Director at VERACYTE, INC. (VCYT) awarded 5,272 restricted stock units

Rhea-AI Filing Summary

Shafer David Brent reported acquisition or exercise transactions in this Form 4 filing.

VERACYTE, INC. director David Brent Shafer received a grant of 5,272 restricted stock units on June 11, 2026 as equity compensation. These units vest in full on the first anniversary of the grant date or immediately before the next annual stockholder meeting, if earlier, and also fully vest upon a change in control. Following this award, Shafer directly holds 31,100 shares of Veracyte common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shafer David Brent

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,272	$0.00	--

Holdings After Transaction: Common Stock — 31,100 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 5,272 units Shares held after transaction: 31,100 shares Grant date: June 11, 2026

3 metrics

RSUs granted 5,272 units Restricted stock units awarded on June 11, 2026

Shares held after transaction 31,100 shares Direct common stock holdings following the award

Grant date June 11, 2026 Date restricted stock units were awarded

Key Terms

Restricted stock units, change in control, annual meeting of stockholders

3 terms

Restricted stock units financial

"Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

change in control financial

"the restricted stock units vest in full in the event of a change in control of the Issuer"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

annual meeting of stockholders financial

"or immediately prior to the Company's next annual meeting of stockholders, if earlier"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shafer David Brent

(Last) (First) (Middle)

6000 SHORELINE COURT

SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		5,272(1)	A	$0	31,100	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did VERACYTE, INC. (VCYT) report for David Brent Shafer?

VERACYTE, INC. reported that director David Brent Shafer received 5,272 restricted stock units on June 11, 2026. This is a stock-based compensation grant, not an open-market purchase or sale, and increases his direct common stock holdings to 31,100 shares.

How many shares did VCYT director David Brent Shafer hold after this Form 4 transaction?

After the reported grant, David Brent Shafer directly holds 31,100 shares of Veracyte common stock. This total includes the impact of the 5,272 restricted stock units awarded on June 11, 2026, as disclosed in the Form 4 filing.

What are the vesting terms of the 5,272 restricted stock units granted by VERACYTE, INC. (VCYT)?

The 5,272 restricted stock units vest in full on the first anniversary of the June 11, 2026 grant date or immediately before Veracyte’s next annual stockholder meeting, if earlier. They also fully vest upon a change in control of the issuer, according to the footnote.

Is the VCYT Form 4 transaction a stock purchase or a compensation award?

The Form 4 shows a compensation award, not a market trade. Code “A” indicates a grant or award acquisition of 5,272 restricted stock units, with a stated price of $0.0000 per share, reflecting stock-based compensation rather than an open-market purchase.

Does the Veracyte (VCYT) insider grant include any special protection on change in control?

Yes. The restricted stock units granted to director David Brent Shafer vest in full if there is a change in control of Veracyte. This provision ensures the award becomes fully vested if the company undergoes a qualifying control transaction.